Legal & General Group Plc Has $199.49 Million Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Legal & General Group Plc reduced its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 14.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,565,151 shares of the medical device company's stock after selling 446,202 shares during the period. Legal & General Group Plc owned approximately 0.66% of DexCom worth $199,492,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of DXCM. Versant Capital Management Inc bought a new stake in shares of DexCom in the 4th quarter worth approximately $25,000. Private Trust Co. NA increased its holdings in shares of DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after buying an additional 245 shares in the last quarter. TD Private Client Wealth LLC lifted its position in shares of DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after acquiring an additional 167 shares during the last quarter. Larson Financial Group LLC lifted its position in shares of DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after acquiring an additional 137 shares during the last quarter. Finally, Heck Capital Advisors LLC bought a new stake in shares of DexCom during the 4th quarter worth $38,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on DXCM shares. Mizuho initiated coverage on DexCom in a report on Thursday, April 10th. They set an "outperform" rating and a $85.00 target price for the company. Citigroup upped their price objective on shares of DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a research note on Tuesday, March 4th. Redburn Atlantic raised shares of DexCom from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Morgan Stanley upped their price target on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. Finally, Robert W. Baird raised shares of DexCom from a "neutral" rating to an "outperform" rating and boosted their target price for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Five research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, DexCom presently has a consensus rating of "Moderate Buy" and a consensus price target of $99.00.

Remove Ads

DexCom Stock Up 1.4 %

DexCom stock traded up $0.91 during mid-day trading on Tuesday, hitting $68.30. 1,381,634 shares of the company's stock were exchanged, compared to its average volume of 4,182,377. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $139.24. The stock has a 50 day moving average of $76.49 and a two-hundred day moving average of $76.68. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The stock has a market cap of $26.78 billion, a P/E ratio of 47.76, a P/E/G ratio of 2.30 and a beta of 1.50.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Kevin R. Sayer sold 33,359 shares of the business's stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the transaction, the chief executive officer now owns 319,037 shares of the company's stock, valued at approximately $27,727,505.67. The trade was a 9.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the sale, the chief operating officer now directly owns 268,644 shares of the company's stock, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 105,009 shares of company stock valued at $8,044,178. Company insiders own 0.30% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.